The PRESTO (prevention of restenosis with tranilast and its outcomes) protocol: A double-blind, placebo-controlled trial

David Holmes, Peter Fitzgerald, Sheldon Goldberg, J. M. LaBlanche, A. Michael Lincoff, Michael Savage, P. W. Serruys, James Willerson, Jeffrey R. Granett, Robert Chan, Neil H. Shusterman, Marcia Poland

Research output: Contribution to journalArticle

58 Scopus citations

Abstract

Background: Tranilast is a unique drug in clinical development for the prevention of restenosis after percutaneous transluminal coronary revascularization (PTCR). Tranilast interferes with proliferation and migration of vascular medial smooth muscle cells induced by platelet-derived growth factor and transforming growth factor β1. Collagen synthesis in vascular medial smooth muscle cells is inhibited by tranilast, which also inhibits the release or production of cyclooxygenase-2 and restores cytokine- induced nitric oxide production. These mechanisms may contribute to the reduction of angiographic restenosis after coronary intervention previously reported in clinical studies. Methods: The primary objective of this multicenter study of 11,500 patients is to compare the composite clinical event rate of death, myocardial infarction, or the need for ischemia-driven target vessel revascularization of tranilast (300 and 450 mg twice daily) for 1 or 3 months with that of placebo in patients undergoing PTCR with or without stenting for single or multiple vessels over a 9-month period. The lesions can be de novo or restenotic. All revascularization procedures and the use of glycoprotein IIb/IIIa agents are permitted. The inclusion criteria are meant to allow an 'all comer' approach for generalization of results to the broadest possible PTCR population. A subset population (n = 2000) will undergo 9-month follow-up angiography, 1000 of which will also undergo intravascular ultrasound (n- 1000). This study is the first tranilast trial to be conducted in a Western population to confirm the improved angiographic findings reported in Japanese patients and to determine if the clinical sequelae of restenosis are also reduced Conclusion: This multicenter study is the largest restenosis trial planned to date. If will test whether tranilast, a drug with multiple actions aimed at affecting proliferation and migration of vascular smooth muscle cells, can reduce clinical, angiographic, and intravascular ultrasound assessments of restenosis.

Original languageEnglish (US)
Pages (from-to)23-31
Number of pages9
JournalAmerican heart journal
Volume139
Issue number1 I
DOIs
StatePublished - Jan 1 2000

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'The PRESTO (prevention of restenosis with tranilast and its outcomes) protocol: A double-blind, placebo-controlled trial'. Together they form a unique fingerprint.

  • Cite this

    Holmes, D., Fitzgerald, P., Goldberg, S., LaBlanche, J. M., Lincoff, A. M., Savage, M., Serruys, P. W., Willerson, J., Granett, J. R., Chan, R., Shusterman, N. H., & Poland, M. (2000). The PRESTO (prevention of restenosis with tranilast and its outcomes) protocol: A double-blind, placebo-controlled trial. American heart journal, 139(1 I), 23-31. https://doi.org/10.1016/S0002-8703(00)90304-1